At bioMONTR Labs, we believe in nurturing and re-investing in the scientific community. As a key opinion leader laboratory, we take the opportunity to publish and present the exciting results from many of our assay development efforts. Summaries are provided below for a few of our recent publications/presentations. Contact us if you are interested in learning more.
- Proof of Concept: Novel Plasma Separation Cards for HCV/HIV Quantification (Presented at 2015 HEP DART in Maui, HI) Summary: This study evaluated the performance of a novel prototype plasma separation card composed of a polysulfone separation membrane and absorbent collection pad allowing the separation of cellular components and collection/stabilization of plasma at ambient conditions.
- Low-Level HIV RNA Declines Over Time in CSF but not in Plasma (Presented at 2013 CROI in Atlanta, GA) Summary: This study assayed CSF and plasma samples from ART-treated individuals using an assay capable of quantitating HIV RNA to 2 cp/mL to determine the correlates of low-level HIV RNA with disease, treatment and neurocognitive characteristics.
- Case Study: Driving Specialized Testing Through Assay Development (Presented at the G2 Intelligence MDx Conference, September 13-14, 2012) Summary: Charting the development of a molecular diagnostic assay for an unmet clinical need. Describe the potential benefits of collaborative relationships with pharma and external researchers in bringing up a novel test.
- New HIV-1 SuperLow Assay For Viral Load Monitoring (Presented at the 2011 Association for Molecular Pathology Annual Meeting in Grapevine, Texas) Summary: Performance review of bioMONTR's HIV-1 SuperLow Assay for real-time HIV-1 quantitation. The RESEARCH USE ONLY assay has a validated 95% hit rate of 15 c/mL and a reportable range of 2 to 10M c/mL. The HIV-1 SuperLow Assay will be a valuable tool for monitoring HIV-1 viral load and patient response in drug development and clinical trial programs.
- Utility of HIV-1 EQ SuperLow Viral load Testing in HIV-associated Cognitive Impairment (Presented at the 2010 III International Clinical Virology Symposium and Advances in Vaccines in Buenos Aires, Argentina) Summary: This study assessed whether low levels of HIV in cerebrospinal fluid (CSF) were associated with inter-individual differences in ART regimens and neuropsychological (NP) performance using bioMONTR's HIV-1 SuperLow assay.